The estimated Net Worth of Dov A Md Goldstein is at least $61.8 Milion dollars as of 18 June 2021. Dov Goldstein owns over 8,000 units of NeuBase Therapeutics stock worth over $11,340 and over the last 11 years he sold NBSE stock worth over $60,950,775. In addition, he makes $847,371 as Independent Director at NeuBase Therapeutics.
Sign up
Dov Goldstein NBSE stock SEC Form 4 insiders trading
Dov has made over 12 trades of the NeuBase Therapeutics stock since 2013, according to the Form 4 filled with the SEC. Most recently he bought 8,000 units of NBSE stock worth $38,000 on 18 June 2021.
The largest trade he's ever made was selling 937,600 units of NeuBase Therapeutics stock on 5 January 2017 worth over $3,197,216. On average, Dov trades about 69,832 units every 81 days since 2013. As of 18 June 2021 he still owns at least 30,000 units of NeuBase Therapeutics stock.
You can see the complete history of Dov Goldstein stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dov Goldstein biography
Dr. Dov A. Goldstein M.D. serves as Independent Director of the Company. is Director of the Company. Dr. Goldstein served as a Managing Partner at Aisling Capital, a private investment firm, from 2014 to October 2017, Partner from 2008 to 2014 and a principal at Aisling Capital from 2006 to 2008. Dr. Goldstein served as the Chief Financial Officer of Loxo Oncology, Inc. between July 2014 and January 2015, and was its acting Chief Financial Officer from January 2015 to May 2015. From 2000 to 2005, Dr. Goldstein served as Chief Financial Officer of Vicuron Pharmaceuticals, Inc., which was acquired by Pfizer, Inc. in September 2005. Prior to joining Vicuron, Dr. Goldstein was Director of Venture Analysis at HealthCare Ventures. Dr. Goldstein also completed an internship in the Department of Medicine at Columbia-Presbyterian Hospital. Dr. Goldstein serves as a director at ADMA Biologics, Inc. (Nasdaq: ADMA). He also previously served as a director of Loxo Oncology, Inc. (Nasdaq: LOXO), Esperion Therapeutics, Inc. (Nasdaq: ESPR), and Cempra, Inc. (which was acquired by Melinta Therapeutics, Inc.). Dr. Goldstein received a B.S. from Stanford University, an M.B.A. from Columbia Business School and an M.D. from Yale School of Medicine. Goldstein’s medical training and his experience in the biopharmaceutical industry as a venture capital investor, as an executive of Vicuron and a member of the boards of directors of other biopharmaceutical companies, as well as his experience in financial matters and his service on compensation committees, qualify him to serve as a member of our board of directors.
What is the salary of Dov Goldstein?
As the Independent Director of NeuBase Therapeutics, the total compensation of Dov Goldstein at NeuBase Therapeutics is $847,371. There are 2 executives at NeuBase Therapeutics getting paid more, with Dietrich Stephan having the highest compensation of $3,677,280.
How old is Dov Goldstein?
Dov Goldstein is 52, he's been the Independent Director of NeuBase Therapeutics since 2019. There are 5 older and 3 younger executives at NeuBase Therapeutics. The oldest executive at NeuBase Therapeutics, Inc. is Franklyn Prendergast, 75, who is the Independent Director.
What's Dov Goldstein's mailing address?
Dov's mailing address filed with the SEC is C/O 350 TECHNOLOGY DRIVE, FOURTH FLOOR, , PITTSBURGH, PA, 15219.
Insiders trading at NeuBase Therapeutics
Over the last 5 years, insiders at NeuBase Therapeutics have traded over $713,184 worth of NeuBase Therapeutics stock and bought 177,514 units worth $548,788 . The most active insiders traders include Dov A Md Goldstein, Dietrich A Stephan a Samuel Backenroth. On average, NeuBase Therapeutics executives and independent directors trade stock every 56 days with the average trade being worth of $37,929. The most recent stock trade was executed by Corp Symetryx on 14 September 2023, trading 282,445 units of NBSE stock currently worth $375,652.
What does NeuBase Therapeutics do?
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1; NT0300, a PATrOL-enabled therapeutic treatment to target the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.
What does NeuBase Therapeutics's logo look like?
Complete history of Dov Goldstein stock trades at Adma Biologics Inc, Esperion Therapeutics a NeuBase Therapeutics
NeuBase Therapeutics executives and stock owners
NeuBase Therapeutics executives and other stock owners filed with the SEC include:
-
Dietrich Stephan,
President, Chief Executive Officer, Director -
Sam Backenroth,
Chief Financial Officer, Treasurer, Secretary -
Eric Richman,
Independent Director -
Franklyn Prendergast,
Independent Director -
Diego Miralles,
Independent Director -
Dov Goldstein,
Independent Director -
Dr. Dietrich A. Stephan Ph.D.,
Founder, Pres, CEO, Chairman & Interim CFO -
Dr. William Roland Mann MBA, Ph.D.,
Chief Operating Officer -
Samuel Backenroth,
CFO, Treasurer & Sec. -
Dan Ferry,
IR Contact Officer -
William Mann,
Chief Operating Officer -
Dr. Sandra Rojas-Caro M.D.,
Chief Medical Officer -
Shannon McCarthy,
Chief People Officer -
Alan Scrivner J.D.,
VP of IP & Legal -
Dr. Anthony Rossomando Ph.D.,
Chief Technology Officer -
Dr. Robert Zamboni Ph.D.,
Chief of Preclinical Devel. & Member of Scientific Advisory Board -
Dr. Robert Friedlander M.D.,
Consulting Chief Medical Officer -
Dr. Curt Bradshaw Ph.D.,
Chief Scientific Officer -
Eric J Ende,
Director -
Curt Bradshaw,
Chief Scientific Officer -
Gerald J Mc Dougall,
Director -
Kianoush Motesharei,
See Remarks -
Todd P. Branning,
Chief Financial Officer -
Corp Symetryx,
10% owner -
Dietrich A Stephan,
Founder and CEO